筋強直性ジストロフィー1型(END-DM1)におけるバイオマーカーと臨床エンドポイントの確立
Building on previous work of the Myotonic Dystrophy Clinical Research Network (DMCRN), the present study seeks to overcome insufficient data on natural history; lack of reliable biomarkers; and incomplete characterization and limited biological understanding of the phenotypic heterogeneity of Myotonic Dystrophy 1 by examining strategies to improve the reliability by making further refinements in our sample collection and analysis procedures by developing strategies for managing patient heterogeneity going forward.
Funding Source- FDA OOPD
調査の概要
状態
条件
詳細な説明
Approximately 700 adult participants (18 to 70 years old, inclusive) with DM1 will be enrolled at 15 centers (up to 70 patients will be recruited at each site). No treatment will be administered as part of this study. Participants will receive standard of care as determined by the investigators. Study visits occur at baseline/0 months, 12 months, and 24 months. Few restrictions are placed on participation in the study because the investigators aim to capture the full spectrum of disease severity.
Muscle biopsy sub-study: Studies of splicing biomarkers in muscle biopsy samples will be conducted on a subset of 95 participants. These participants will have an additional study visit at 3 months.
Longitudinal muscle biopsy sub-study: Up to 30 individuals who have had a prior muscle biopsy as part of a DMCRN study will be asked to undergo another biopsy greater than 24 months after the prior biopsy. These participants will have an additional ad hoc biopsy visit.
COVID-19 sub-study: To evaluate severity of illness and response to COVID-19 vaccination in DM1 patients compared to corresponding data available about the general population, END-DM1 study participants will be asked to complete a one-time survey about COVID-19 experiences. A subset of those participants' blood samples will be analyzed to understand immunoglobulin response to infection and vaccination in DM1 patients.
Actigraphy sub-study: To assess daily physical activity in individuals with DM1 and evaluate physical activity changes over a 12-24 month period related to disease progression, a subset of participants will be asked to wear a small, wireless activity monitor while performing functional assessments described in the main study. Those participants will be asked to wear the activity monitor for 7 days following their research visit. Those participants will be asked to complete additional questionnaires.
Handheld Dynamometry sub-study: To evaluate additional muscle strength methods, a subset of participants will be asked to complete additional strength testing using either the MEDup or MicroFET handheld dynamometry device on the same day as their END-DM1 main study visit. Those participants will be asked to return to the clinic for a second visit within 10 days of the END-DM1 study visit to repeat the handheld dynamometry assessments and complete additional strength measures.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Ruby Langeslay
- 電話番号:804-828-8481
- メール:ruby.langeslay@vcuhealth.org
研究連絡先のバックアップ
- 名前:Jennifer Raymond
- 電話番号:804-828-6318
- メール:jennifer.raymond@vcuhealth.org
研究場所
-
-
California
-
La Jolla、California、アメリカ、92703
- 募集
- University of California, San Diego
-
主任研究者:
- Chamindra Laverty, MD
-
コンタクト:
- Elizabeth Moreno
- メール:e4moreno@health.ucsd.edu
-
コンタクト:
- Gabriella Penner
- メール:gpenner@health.ucsd.edu
-
Los Angeles、California、アメリカ、90095
- 募集
- University of California, Los Angeles
-
主任研究者:
- Perry Shieh, MD, PhD
-
コンタクト:
- Dennis Fernando
- 電話番号:310-825-3264
- メール:DeFernando@mednet.ucla.edu
-
-
Colorado
-
Denver、Colorado、アメリカ、80204
- 募集
- University of Colorado - Denver
-
コンタクト:
- Alyssa Avilez
- 電話番号:303-724-4644
- メール:alyssa.avilez@cuanschutz.edu
-
コンタクト:
- Brianna Blume
- 電話番号:303-724-6386
- メール:brianna.blume@cuanschutz.edu
-
主任研究者:
- Matthew Wicklund, MD
-
-
Florida
-
Gainesville、Florida、アメリカ、32611
- 募集
- University of Florida
-
主任研究者:
- Sankarsubramoney Subramony, MD
-
コンタクト:
- Donovan Lott
- メール:djlottpt@phhp.ufl.edu
-
コンタクト:
- Whitney Miller
- メール:whitney.miller@neurology.ufl.edu
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- 募集
- University of Iowa
-
主任研究者:
- Andrea Swenson, MD
-
コンタクト:
- Maegan Tyrrell
- 電話番号:319-356-8323
- メール:maegan-tyrrell@uiowa.edu
-
コンタクト:
- Loraine Brenner
- メール:loraine-brenner@uiowa.edu
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- 募集
- Kansas University Medical Center
-
主任研究者:
- Jeffrey Statland, MD
-
コンタクト:
- Michaela Walker
- メール:mwalker20@kumc.edu
-
コンタクト:
- Rebecca Clay
- メール:rclay@kumc.edu
-
-
New York
-
Rochester、New York、アメリカ、14642
- 募集
- University of Rochester
-
コンタクト:
- Jeanne Dekdebrun
- 電話番号:585-276-4611
- メール:Jeanne_dekdebrun@urmc.rochester.edu
-
主任研究者:
- Johanna Hamel, MD
-
コンタクト:
- Jim Hilbert
- 電話番号:585-273-5590
- メール:james_hilbert@urmc.rochester.edu
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- 募集
- Ohio State University
-
コンタクト:
- Kaneshia Hives
- 電話番号:614-685-5661
- メール:Kaneshia.Hives@osumc.edu
-
コンタクト:
- Lischele Watkins
- メール:lischele.watkins@osumc.edu
-
主任研究者:
- Bakri Elsheikh, MD
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- Houston Methodist Neurological Institute
-
主任研究者:
- Erika P. Greene
-
コンタクト:
- Kadeesia Brown
- 電話番号:346-238-2295
- メール:kbrown5@houstonmethodist.org
-
-
Virginia
-
Richmond、Virginia、アメリカ、23298
- 募集
- Virginia Commonwealth University
-
主任研究者:
- Nicholas Johnson, MD
-
コンタクト:
- Jodie Howell
- メール:jodie.howell@vcuhealth.org
-
コンタクト:
- Carino Jennings
- メール:Carino.Garza@vcuhealth.org
-
-
-
-
-
London、イギリス
- 募集
- University College London
-
コンタクト:
- Chris Turner
- メール:chris.turner7@nhs.net
-
主任研究者:
- Chris Turner
-
コンタクト:
- Iqraa Afzal
- メール:iqraa.afzal@nhs.net
-
London、イギリス
- 募集
- St. George's, University of London
-
コンタクト:
- Emma Matthews
- 電話番号:020 8725 4162
- メール:ematthew@sgul.ac.uk
-
主任研究者:
- Emma Matthews
-
-
-
-
-
Milan、イタリア
- 完了
- Centro Clinico NeMO
-
-
-
-
-
Nijmegen、オランダ
- 募集
- Radboud University Medical Center
-
コンタクト:
- Baziel vanEngelen
- 電話番号:(024) 366 8374
- メール:Baziel.vanEngelen@radboudumc.nl
-
主任研究者:
- Baziel van Engelen, MD
-
コンタクト:
- Monique Plieger
- メール:Monique.Plieger@radboudumc.nl
-
-
-
-
-
Québec、カナダ
- 積極的、募集していない
- Université de Sherbrooke
-
-
-
-
-
München、ドイツ
- 募集
- Friedrich Baur Institute, Ludwig-Maximilians-Universität München
-
コンタクト:
- Benedikt Schoser
- 電話番号:+49 (0)89 4400 57400
- メール:benedikt.schoser@med.lmu.ede
-
主任研究者:
- Benedikt Schoser, FEAN
-
コンタクト:
- Corinna Wirner-Piotrowski
- 電話番号:+49 89 4400 57400
- メール:Corinna.Wirner@med.uni-muenchen.de
-
-
-
-
-
Auckland、ニュージーランド
- 募集
- University of Auckland
-
主任研究者:
- Richard Roxburgh
-
コンタクト:
- Miriam Rodrigues
- 電話番号:021896662
- メール:mrodrigues@adhb.govt.nz
-
コンタクト:
- Neerja Singh
- メール:neerja.singh@auckland.ac.nz
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
DM1 has a prevalence rate of approximately 1 per 2,300. There are no expected gender differences. Both men and women will be selected for this study.
Children with DM1 are not included in this project because the pathophysiological basis of congenital and childhood DM1 appears to be mechanistically distinct.
説明
Inclusion criteria:
- Age 18 to 70 (inclusive)
- Competent to provide informed consent
- Clinical diagnosis of DM1 based on research criteria1 or positive genetic test
- Comment: The clinical research criteria require myotonia, muscle weakness in a characteristic distribution, and history of similar findings in a first degree relative. Genetic testing confirmed the diagnosis of DM1 in > 99% of individuals who satisfied these criteria.2
Exclusion criteria:
- Symptomatic renal or liver disease, uncontrolled diabetes or thyroid disorder, or active malignancy other than skin cancer.
- Current alcohol or substance abuse
- Concurrent enrollment in clinical trial for DM1, or participation in trial within 6 months of entry.
- Concurrent pregnancy or planned pregnancy during the course of the study.
- Concurrent medical condition that would, in the opinion of the investigator or clinical evaluator, compromise performance on study measures.
- Note: non-ambulatory participants are not excluded, but are limited to <15% of enrollment.
Inclusion criteria for participants in the muscle biopsy sub-study:
• Of the 95 patients undergoing the tibialis anterior muscle biopsy, at least half will have at least moderate weakness of ankle dorsiflexion, defined as MRC score ≤ 4+. This is in order to obtain a muscle tissue sample in a person more severely affected with myotonic dystrophy. Approximately 10 patients at each site will undergo the muscle biopsy.
Exclusion criteria for 95 participants in the muscle biopsy sub-study:
- Known CTG repeat expansion size less than 100 repeats, unless there are clear cut signs of limb weakness and muscle wasting. This is in order to obtain a muscle tissue sample in a person more severely affected with myotonic dystrophy.
- Use of anticoagulant such as warfarin or a direct oral anticoagulant (e.g. dabigatran) due to the increased risk of bleeding.
- Use of aspirin or non-steroidal anti-inflammatory agents should be discontinued 3 days prior to the biopsy procedure, if possible.
- Platelet count <50,000 (if known) due to the increased risk of bleeding.
- History of a bleeding disorder due to the increased risk of bleeding.
- Advanced wasting of tibialis anterior (TA) muscle that precludes needle muscle biopsy in order to ensure that a sample taken would be of muscle and not just fat and fascia.
- Previous muscle biopsy of either TA in order to provide muscle tissue samples of non-biopsied muscles.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:OTHER
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Study Visits
Patients will receive standard of care as determined by their treating physician. Study visits occur at baseline/0 months, 12 months, and 24 months |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in ambulation over 24 months as measured by the 10 meter walk (m/s).
時間枠:12 and 24 months
|
10 meter walk will be measured (m/s) |
12 and 24 months
|
|
Change in respiratory function over 24 months as measured by spirometry, specifically the supine forced vital capacity (FVC).
時間枠:12 and 24 months
|
Supine forced vital capacity (% predicted) |
12 and 24 months
|
|
Percent splicing of DM1-affected splice events
時間枠:3 months
|
RNA sequenced of muscle biopsy samples collected at two different times will be combined and used to calculate a percent splicing index (PMI) |
3 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Longitudinal Muscle Biopsy Sub-study: Characterization of RNA splicing measures over a prolonged period of time (>24 months)
時間枠:24 months
|
RNA sequenced of muscle biopsy samples collected at two different times will be combined and used to calculate a percent splicing index (PMI) |
24 months
|
|
Longitudinal Muscle Biopsy Sub-study: Characterization of functional endpoints over a prolonged period of time (>24 months)
時間枠:24 months
|
10-meter walk/run, grip strength, ADF (ankle dorsiflexion) strength, supine FVC (forced vital capacity) |
24 months
|
|
COVID-19 Sub-study: Data from DM1 patients or caregivers about COVID-19 illness and vaccination experience, severity of illness and response to vaccination in DM1 patients compared to corresponding data available about the general population.
時間枠:24 months
|
To evaluate the severity and rate of COVID-19 infection in patients with DM1 compared to the general population symptomatic response to COVID-19 vaccination in DM1 patients |
24 months
|
|
COVID-19 Sub-study: Immunoglobulin profile and measles titers, and COVID-19 IgG titers
時間枠:24 months
|
To understand immunoglobulin response to infection and vaccination in DM1 patients |
24 months
|
|
Actigraphy Sub-study: Feasibility of measuring daily physical activity in individuals with DM1 in a multi-site study
時間枠:24 months
|
Participants will be asked to wear an activity monitor for 7 days following their in-clinic END-DM1 study visit to evaluate whether this type of activity monitoring is feasible in future trials. |
24 months
|
|
Actigraphy Sub-study: Objective daily physical activity using wireless accelerometry (ActiGraph), and comparison to normative values and patient reported physical activity.
時間枠:24 months
|
Participants will be asked to wear an activity monitor for 7 days following their in-clinic END-DM1 study visit and report physical activity, to establish physical activity data in the DM1 population. |
24 months
|
|
Actigraphy Sub-study: Physical activity changes over a 12-24 month period related to disease progression.
時間枠:24 months
|
Participants will wear the wireless activity monitor during the functional and strength measures, and complete additional study questionnaires at their regular END-DM1 study visits. |
24 months
|
|
Handheld Dynamometry Sub-study: Inter-rater reliability, standard error of measurement, and minimal detectable change of Maximal Isometric Muscle Strength force values obtained with the MEDup and MicroFET handheld dynamometers in adults with DM1
時間枠:24 months
|
Participants will be assessed using either the MEDup or MicroFET handheld dynamometer on the same day as an END-DM1 main study visit. Participants will complete a second visit +/- 10 days from that visit where HHD will be assessed using the same HHD method (either MEDup or MicroFET) used at the HHD visit. Additional functional and strength assessments will be captured at this visit. |
24 months
|
|
Handheld Dynamometry Sub-study: Comparison of quantitative muscle strength testing feasibility and validity between MEDup and MicroFET with the existing Fixed-QMT currently used in the END-DM1 study protocol.
時間枠:24 months
|
Data captured for MEDup and MicroFET will be compared to data collected using the Fixed-QMT measures in the main END-DM1 study. |
24 months
|
協力者と研究者
協力者
捜査官
- 主任研究者:Nicholas Johnson, MD、Virginia Commonwealth University
- 主任研究者:Charles Thornton, MD、University of Rochester
出版物と役立つリンク
一般刊行物
- Leeuwenberg KE, Sansone VA, Hamel J, Hung M, Dekdebrun JM, Lizio A, Eichinger K, Gagnon C, Roxburgh RH, Subramony SH, Statland JM, Elsheikh BH, Turner C, Matthews EL, Ragole TE, Sampson JB, Schoser B, Takahashi MP, Wicklund MP, Swenson AJ, Laverty CG, Shieh PB, Greene EP, Raymond J, DeSpain E, Thornton CA, Mul K, Johnson NE; Myotonic Dystrophy Clinical Research Network. Prospective Study of Video Hand Opening Time as a Quantitative Measurement of Myotonia in Patients With Myotonic Dystrophy Type 1. Neurology. 2026 Apr 14;106(7):e214747. doi: 10.1212/WNL.0000000000214747. Epub 2026 Feb 26.
- Mul K, Eichinger K, Hung M, Sansone VA, Gagnon C, Subramony S, Roxburgh RH, Hamel J, Statland JM, Elsheikh B, Turner C, Sampson J, Ragole T, Matthews E, Schoser B, Swenson A, Laverty C, Shieh P, Greene EP, Takahashi M, Wicklund M, Dekdebrun J, Raymond J, DeSpain E, Thornton CA, Johnson NE; Myotonic Dystrophy Clinical Research Network. Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study. PLoS One. 2025 Dec 11;20(12):e0331163. doi: 10.1371/journal.pone.0331163. eCollection 2025.
- Provenzano M, Ikegami K, Bates K, Gaynor A, Hartman JM, Jones A, Butler A, Berggren KN, Dekdebrun J, Hung M, Lapato DM, Kiefer M, Thornton CA, Johnson NE, Hale MA; Myotonic Dystrophy Clinical Research Network (DMCRN). The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1. J Clin Invest. 2025 Jan 7;135(4):e185426. doi: 10.1172/JCI185426.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- HM20014419
- DMCRN (その他の識別子:University of Rochester)
- FD-R-006071 (その他の助成金/資金番号:OPD)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Aggregated and deidentified data will be shared with qualified investigators upon majority approval of the DMCRN investigators.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。